Galderma Drug Patent Portfolio
Galderma owns 11 orange book drugs protected by 83 US patents with Metvixia having the least patent protection, holding only 1 patent. And Soolantra with maximum patent protection, holding 14 patents. Given below is the list of Galderma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10206939 | Treatment of papulopustular rosacea with ivermectin | 13 Mar, 2034 | Active |
| US9089587 | Treatment of papulopustular rosacea with ivermectin | 13 Mar, 2034 | Active |
| US9233117 | Treatment of inflammatory lesions of rosacea with ivermectin | 13 Mar, 2034 | Active |
| US9233118 | Treatment of papulopustular rosacea with ivermectin | 13 Mar, 2034 | Active |
| US9782425 | Treatment of papulopustular rosacea with ivermectin | 13 Mar, 2034 | Active |
| US9084778 | Topical compositions containing a retinoid of the oil-in-water emulsion type | 30 May, 2033 | Active |
| US9498465 | Topical compositions in the form of a gel containing a particular solubilized retinoid | 30 May, 2033 | Active |
| US7807708 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | 19 Jul, 2031 | Active |
| US10201517 | Brimonidine gel compositions and methods of use | 13 Jun, 2031 | Active |
| US8053427 | Brimonidine gel composition | 13 Jun, 2031 | Active |
| US8163725 | Gel compositions and methods of use | 13 Jun, 2031 | Active |
| US8513247 | Methods and compositions for safe and effective treatment of erythema | 25 Mar, 2031 | Active |
| US8513249 | Methods and compositions for safe and effective treatment of erythema | 25 Mar, 2031 | Active |
| US9861631 | Methods and compositions for safe and effective treatment of erythema | 25 Mar, 2031 | Active |
| US9861632 | Methods and compositions for safe and effective treatment of erythema | 25 Mar, 2031 | Active |
| US7998467 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers | 31 May, 2028 | Active |
| US7749532 | Once daily formulations of tetracyclines | 19 Dec, 2027 | Active |
| US8071644 | Combinations of adapalene and benzoyl peroxide for treating acne lesions | 18 Jul, 2027 | Active |
| US8080537 | Combinations of adapalene and benzoyl peroxide for treating acne lesions | 18 Jul, 2027 | Active |
| US8129362 | Combination/association of adapalene and benzoyl peroxide for treating acne lesions | 18 Jul, 2027 | Active |
| US8435502 | Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers | 15 Sep, 2026 | Active |
| US8709392 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers | 15 Sep, 2026 | Active |
| US7915243 | Topical skin care composition | 22 Mar, 2026 | Active |
| US8206740 | Once daily formulations of tetracyclines | 24 Dec, 2025 | Expired |
| US8227507 | Ligands that modulate RAR receptors | 21 Dec, 2025 | Expired |
| US8470871 | Ligands that modulate RAR receptors | 21 Dec, 2025 | Expired |
| US7820186 | Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt | 23 Nov, 2025 | Expired |
| US7439241 | Compounds, formulations, and methods for treating or preventing rosacea | 25 Aug, 2025 | Expired |
| US8231885 | Compounds, formulations, and methods for ameliorating telangiectasis | 24 May, 2025 | Expired |
| US8410102 | Methods and compositions for treating or preventing erythema | 24 May, 2025 | Expired |
| US8426410 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | 24 May, 2025 | Expired |
| US7939516 | Topical skin care composition | 04 May, 2025 | Expired |
| US7579377 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 23 Feb, 2025 | Expired |
| US7964202 | Method for treatment of common acne | 01 Sep, 2024 | Expired |
| US7737181 | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 29 Aug, 2024 | Expired |
| US8859551 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | 25 May, 2024 | Expired |
| US11033565 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US7550440 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8080530 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8093219 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8415311 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8470788 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8815816 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8394405 | Once daily formulations of tetracyclines | 07 Apr, 2024 | Expired |
| US8394406 | Once daily formulations of tetracyclines | 07 Apr, 2024 | Expired |
| US8470364 | Once daily formulations of tetracyclines | 07 Apr, 2024 | Expired |
| US8709478 | Once daily formulations of tetracyclines | 07 Apr, 2024 | Expired |
| US7834060 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US7838558 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US7868044 | Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid | 12 Mar, 2023 | Expired |
| US8703820 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US8729127 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US9381179 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US9387187 | Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US8105618 | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide | 23 Dec, 2022 | Expired |
| US8241649 | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide | 23 Dec, 2022 | Expired |
| US8445543 | Combinations of adapalene and benzoyl peroxide for treating acne lesions | 23 Dec, 2022 | Expired |
| US8809305 | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris | 23 Dec, 2022 | Expired |
| US8936800 | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt | 23 Dec, 2022 | Expired |
| US8785420 | Combination/association of adapalene and benzoyl peroxide for treating acne lesions | 23 Dec, 2022 | Expired |
| US8909305 | Method and system for activating an application on a mobile device | 23 Dec, 2022 | Expired |
| US9814690 | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt | 23 Dec, 2022 | Expired |
| US8653053 | Topical skin care composition | 25 Oct, 2022 | Expired |
| US8247395 | Topical skin care composition | 22 Oct, 2022 | Expired |
| US10058564 | Methods of treating acne | 05 Apr, 2022 | Expired |
| US7211267 | Methods of treating acne | 05 Apr, 2022 | Expired |
| US7232572 | Methods of treating rosacea | 05 Apr, 2022 | Expired |
| US8603506 | Methods of treating acne | 05 Apr, 2022 | Expired |
| US9241946 | Methods of treating acne | 05 Apr, 2022 | Expired |
| US6881726 | Aqueous compositions containing metronidazole | 21 Feb, 2022 | Expired |
| US7348317 | Aqueous compositions containing metronidazole | 21 Feb, 2022 | Expired |
| US7700081 | Foaming compositions for hair care | 03 Jan, 2022 | Expired |
| US7316810 | Foaming composition for washing and treating hair and/or scalp based on an active principle | 17 Jun, 2019 | Expired |
| US8066975 | Foaming composition for washing and treating hair and/or scalp based on an active principle | 17 Jun, 2019 | Expired |
| US8066976 | Foaming compositions for hair care | 17 Jun, 2019 | Expired |
| US6133310 | Method of treatment of rosacea | 26 Apr, 2019 | Expired |
| US5952372 | Method for treating rosacea using oral or topical ivermectin | 18 Sep, 2018 | Expired |
| US5990100 | Composition and method for treatment of psoriasis | 24 Mar, 2018 | Expired |
| US5972920 | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders | 12 Feb, 2018 | Expired |
| US6106848 | Topically applicable O/W emulsions having high glycol content and at least one biologically active agent | 22 Sep, 2017 | Expired |
| US5789395 | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production | 30 Aug, 2016 | Expired |
| US5919775 | Method for inhibiting expression of inducible nitric oxide synthase with tetracycline | 30 Aug, 2016 | Expired |
| US6034267 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | 08 Mar, 2016 | Expired |
Latest Legal Activities on Galderma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Galderma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 May, 2024 | US9498465 |
|
Maintenance Fee Reminder Mailed
Critical
| 08 Apr, 2024 | US8247395 |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Apr, 2024 | US8241649 |
|
Expire Patent
Critical
| 04 Mar, 2024 | US8105618 |
|
Maintenance Fee Reminder Mailed
Critical
| 04 Mar, 2024 | US9387187 |
|
Maintenance Fee Reminder Mailed
Critical
| 26 Feb, 2024 | US9381179 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Jan, 2024 | US8231885 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Jan, 2024 | US8227507 |
|
Expire Patent
Critical
| 01 Jan, 2024 | US8066976 |
|
Expire Patent
Critical
| 01 Jan, 2024 | US8066975 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Oct, 2023 | US8163725 |
|
Maintenance Fee Reminder Mailed
Critical
| 18 Sep, 2023 | US8105618 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 Aug, 2023 | US8129362 |
|
Maintenance Fee Reminder Mailed
Critical
| 17 Jul, 2023 | US8066975 |
|
Maintenance Fee Reminder Mailed
Critical
| 17 Jul, 2023 | US8066976 |
Galderma's Drug Patent Litigations
Galderma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 16, 2014, against patent number US8426410. The petitioner , challenged the validity of this patent, with Jack Dejovin et al as the respondent. Click below to track the latest information on how companies are challenging Galderma's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8603506 | August, 2015 |
Institution Denied
(16 Feb, 2016)
| GALDERMA LABORATORIES, INC. et al. | Dr. Reddy’s Laboratories, Ltd. et al. |
| US8603506 | August, 2015 |
Terminated-Denied
(16 Feb, 2016)
| GALDERMA LABORATORIES, INC. | Dr. Reddy’s Laboratories, Ltd. |
| US8394406 | June, 2013 |
FWD Entered
(09 Dec, 2014)
| ||
| US8394405 | June, 2013 |
Final Written Decision
(09 Dec, 2014)
| Supernus Pharmaceuticals, Inc. et al. | Amneal Pharamceuticals, LLC et al. |
| US8394405 | June, 2013 |
FWD Entered
(09 Dec, 2014)
| Supernus Pharmaceuticals, Inc. | Amneal Pharamceuticals, LLC |
| US8206740 | June, 2013 |
Final Written Decision
(09 Dec, 2014)
| Supernus Pharmaceuticals, Inc. et al. | Amneal Pharmaceuticals, LLC et al. |
| US8206740 | June, 2013 |
FWD Entered
(09 Dec, 2014)
| ||
| US8394406 | June, 2013 |
Final Written Decision
(09 Dec, 2014)
| Supernus Pharmaceuticals, Inc. et al. | Amneal Pharamceuticals, LLC et al. |
| US7439241 | May, 2014 |
Decision
(16 May, 2014)
| Jack Dejovin et al | |
| US8426410 | May, 2014 |
Decision
(16 May, 2014)
| Jack Dejovin et al | |
Galderma Drug Patents' Oppositions Filed in EPO
Galderma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 26, 2012, by Allergan, Inc.. This opposition was filed on patent number EP04753601A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP13726504A | Apr, 2019 | Generics (U.K.) Limited | Patent maintained as amended |
| EP13728696A | Mar, 2019 | Generics (UK) Ltd | Patent maintained as amended |
| EP08708470A | Mar, 2016 | Generics (U.K.) Limited | Revoked |
| EP11185810A | Apr, 2015 | Beiersdorf AG | Patent maintained as amended |
| EP07787478A | Mar, 2014 | Generics [UK] Limited | Opposition rejected |
| EP04753601A | Jul, 2012 | ALLERGAN, INC. | Patent maintained as amended |
Galderma's Family Patents
Galderma drugs have patent protection in a total of 37 countries. It's US patent count contributes only to 28.2% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Galderma Drug List
Given below is the complete list of Galderma's drugs and the patents protecting them.
1. Aklief
Aklief is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9084778 | Topical compositions containing a retinoid of the oil-in-water emulsion type |
30 May, 2033
(7 years from now)
| Active |
| US9498465 | Topical compositions in the form of a gel containing a particular solubilized retinoid |
30 May, 2033
(7 years from now)
| Active |
| US7807708 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
19 Jul, 2031
(5 years from now)
| Active |
| US8227507 | Ligands that modulate RAR receptors |
21 Dec, 2025
(18 days ago)
| Expired |
| US8470871 | Ligands that modulate RAR receptors |
21 Dec, 2025
(18 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aklief's drug page
2. Clobex
Clobex is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7700081 | Foaming compositions for hair care |
03 Jan, 2022
(4 years ago)
| Expired |
| US7316810 | Foaming composition for washing and treating hair and/or scalp based on an active principle |
17 Jun, 2019
(6 years ago)
| Expired |
| US8066975 | Foaming composition for washing and treating hair and/or scalp based on an active principle |
17 Jun, 2019
(6 years ago)
| Expired |
| US8066976 | Foaming compositions for hair care |
17 Jun, 2019
(6 years ago)
| Expired |
| US5990100 | Composition and method for treatment of psoriasis |
24 Mar, 2018
(7 years ago)
| Expired |
| US5972920 | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
12 Feb, 2018
(7 years ago)
| Expired |
| US6106848 | Topically applicable O/W emulsions having high glycol content and at least one biologically active agent |
22 Sep, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clobex's drug page
3. Differin
Differin is protected by 9 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7998467 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
31 May, 2028
(2 years from now)
| Active |
| US8435502 | Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers |
15 Sep, 2026
(8 months from now)
| Active |
| US8709392 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
15 Sep, 2026
(8 months from now)
| Active |
| US7579377 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
23 Feb, 2025
(10 months ago)
| Expired |
| US7737181 | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
29 Aug, 2024
(1 year, 4 months ago)
| Expired |
| US7834060 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(2 years ago)
| Expired |
| US7838558 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(2 years ago)
| Expired |
| US7868044 | Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid |
12 Mar, 2023
(2 years ago)
| Expired |
| US8703820 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Differin's drug page
4. Epiduo
Epiduo is protected by 10 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071644 | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
18 Jul, 2027
(1 year, 6 months from now)
| Active |
| US8080537 | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
18 Jul, 2027
(1 year, 6 months from now)
| Active |
| US8129362 | Combination/association of adapalene and benzoyl peroxide for treating acne lesions |
18 Jul, 2027
(1 year, 6 months from now)
| Active |
| US8445543 | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
12 Jul, 2027
(1 year, 6 months from now)
| Active |
| US7820186 | Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
23 Nov, 2025
(a month ago)
| Expired |
| US7964202 | Method for treatment of common acne |
01 Sep, 2024
(1 year, 4 months ago)
| Expired |
| US8105618 | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide |
23 Dec, 2022
(3 years ago)
| Expired |
| US8241649 | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide |
23 Dec, 2022
(3 years ago)
| Expired |
| US8809305 | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris |
23 Dec, 2022
(3 years ago)
| Expired |
| US8936800 | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
23 Dec, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epiduo's drug page
5. Epiduo Forte
Epiduo Forte is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8703820 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(2 years ago)
| Expired |
| US8729127 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(2 years ago)
| Expired |
| US9381179 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(2 years ago)
| Expired |
| US9387187 | Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(2 years ago)
| Expired |
| US8445543 | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
23 Dec, 2022
(3 years ago)
| Expired |
| US8785420 | Combination/association of adapalene and benzoyl peroxide for treating acne lesions |
23 Dec, 2022
(3 years ago)
| Expired |
| US8809305 | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris |
23 Dec, 2022
(3 years ago)
| Expired |
| US8909305 | Method and system for activating an application on a mobile device |
23 Dec, 2022
(3 years ago)
| Expired |
| US8936800 | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
23 Dec, 2022
(3 years ago)
| Expired |
| US9814690 | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
23 Dec, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epiduo Forte's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Metrogel
Metrogel is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6881726 | Aqueous compositions containing metronidazole |
21 Feb, 2022
(3 years ago)
| Expired |
| US7348317 | Aqueous compositions containing metronidazole |
21 Feb, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Metrogel's drug page
7. Metvixia
Metvixia is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6034267 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
08 Mar, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Metvixia's drug page
8. Mirvaso
Mirvaso is protected by 12 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10201517 | Brimonidine gel compositions and methods of use |
13 Jun, 2031
(5 years from now)
| Active |
| US8053427 | Brimonidine gel composition |
13 Jun, 2031
(5 years from now)
| Active |
| US8163725 | Gel compositions and methods of use |
13 Jun, 2031
(5 years from now)
| Active |
| US8513247 | Methods and compositions for safe and effective treatment of erythema |
25 Mar, 2031
(5 years from now)
| Active |
| US8513249 | Methods and compositions for safe and effective treatment of erythema |
25 Mar, 2031
(5 years from now)
| Active |
| US9861631 | Methods and compositions for safe and effective treatment of erythema |
25 Mar, 2031
(5 years from now)
| Active |
| US9861632 | Methods and compositions for safe and effective treatment of erythema |
25 Mar, 2031
(5 years from now)
| Active |
| US7439241 | Compounds, formulations, and methods for treating or preventing rosacea |
25 Aug, 2025
(4 months ago)
| Expired |
| US8231885 | Compounds, formulations, and methods for ameliorating telangiectasis |
24 May, 2025
(7 months ago)
| Expired |
| US8410102 | Methods and compositions for treating or preventing erythema |
24 May, 2025
(7 months ago)
| Expired |
| US8426410 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
24 May, 2025
(7 months ago)
| Expired |
| US8859551 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
25 May, 2024
(1 year, 7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mirvaso's drug page
9. Oracea
Oracea is protected by 13 patents, out of which 12 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7749532 | Once daily formulations of tetracyclines |
19 Dec, 2027
(1 year, 11 months from now)
| Active |
| US8206740 | Once daily formulations of tetracyclines |
24 Dec, 2025
(15 days ago)
| Expired |
| US8394405 | Once daily formulations of tetracyclines |
07 Apr, 2024
(1 year, 9 months ago)
| Expired |
| US8394406 | Once daily formulations of tetracyclines |
07 Apr, 2024
(1 year, 9 months ago)
| Expired |
| US8470364 | Once daily formulations of tetracyclines |
07 Apr, 2024
(1 year, 9 months ago)
| Expired |
| US8709478 | Once daily formulations of tetracyclines |
07 Apr, 2024
(1 year, 9 months ago)
| Expired |
| US10058564 | Methods of treating acne |
05 Apr, 2022
(3 years ago)
| Expired |
| US7211267 | Methods of treating acne |
05 Apr, 2022
(3 years ago)
| Expired |
| US7232572 | Methods of treating rosacea |
05 Apr, 2022
(3 years ago)
| Expired |
| US8603506 | Methods of treating acne |
05 Apr, 2022
(3 years ago)
| Expired |
| US9241946 | Methods of treating acne |
05 Apr, 2022
(3 years ago)
| Expired |
| US5789395 | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
30 Aug, 2016
(9 years ago)
| Expired |
| US5919775 | Method for inhibiting expression of inducible nitric oxide synthase with tetracycline |
30 Aug, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oracea's drug page
10. Soolantra
Soolantra is protected by 14 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10206939 | Treatment of papulopustular rosacea with ivermectin |
13 Mar, 2034
(8 years from now)
| Active |
| US9089587 | Treatment of papulopustular rosacea with ivermectin |
13 Mar, 2034
(8 years from now)
| Active |
| US9233117 | Treatment of inflammatory lesions of rosacea with ivermectin |
13 Mar, 2034
(8 years from now)
| Active |
| US9233118 | Treatment of papulopustular rosacea with ivermectin |
13 Mar, 2034
(8 years from now)
| Active |
| US9782425 | Treatment of papulopustular rosacea with ivermectin |
13 Mar, 2034
(8 years from now)
| Active |
| US11033565 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(1 year, 8 months ago)
| Expired |
| US7550440 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(1 year, 8 months ago)
| Expired |
| US8080530 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(1 year, 8 months ago)
| Expired |
| US8093219 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(1 year, 8 months ago)
| Expired |
| US8415311 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(1 year, 8 months ago)
| Expired |
| US8470788 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(1 year, 8 months ago)
| Expired |
| US8815816 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(1 year, 8 months ago)
| Expired |
| US6133310 | Method of treatment of rosacea |
26 Apr, 2019
(6 years ago)
| Expired |
| US5952372 | Method for treating rosacea using oral or topical ivermectin |
18 Sep, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Soolantra's drug page
11. Tri-luma
Tri-luma is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7915243 | Topical skin care composition |
22 Mar, 2026
(2 months from now)
| Active |
| US7939516 | Topical skin care composition |
04 May, 2025
(8 months ago)
| Expired |
| US8653053 | Topical skin care composition |
25 Oct, 2022
(3 years ago)
| Expired |
| US8247395 | Topical skin care composition |
22 Oct, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tri-luma's drug page